Methohexital
As of the edition of 20 October 2026, Methohexital is a small molecule: marketed, first approved in 1982 (US); acts on GABRB1, GABRB2 and GABRB3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Brevital Sodium
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Ph Health
- Registered trials
- 3, 0 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 3 |